 Mina Pantcheva
Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 22 | 2025 | 243 | 4.780 |
Why?
| | Ocular Hypertension | 8 | 2025 | 68 | 3.560 |
Why?
| | Intraocular Pressure | 24 | 2025 | 316 | 3.240 |
Why?
| | Glaucoma, Open-Angle | 8 | 2023 | 104 | 2.750 |
Why?
| | Uveitis | 4 | 2025 | 148 | 2.630 |
Why?
| | Phacoemulsification | 10 | 2025 | 120 | 2.230 |
Why?
| | Trabeculectomy | 7 | 2025 | 74 | 1.940 |
Why?
| | Laser Coagulation | 5 | 2025 | 72 | 1.430 |
Why?
| | Trabecular Meshwork | 7 | 2024 | 79 | 1.400 |
Why?
| | Visual Acuity | 8 | 2025 | 451 | 1.320 |
Why?
| | Disease Management | 2 | 2025 | 641 | 1.140 |
Why?
| | Uveitis, Anterior | 2 | 2019 | 25 | 1.140 |
Why?
| | Cataract | 7 | 2023 | 223 | 1.110 |
Why?
| | Ciliary Body | 4 | 2025 | 40 | 1.090 |
Why?
| | Cataract Extraction | 5 | 2024 | 106 | 1.080 |
Why?
| | Endoscopy | 4 | 2025 | 327 | 0.900 |
Why?
| | Antihypertensive Agents | 3 | 2025 | 511 | 0.870 |
Why?
| | Fibronectins | 3 | 2021 | 135 | 0.700 |
Why?
| | Tonometry, Ocular | 8 | 2025 | 103 | 0.700 |
Why?
| | Glycosaminoglycans | 2 | 2022 | 82 | 0.680 |
Why?
| | Chondroitin Sulfates | 2 | 2020 | 35 | 0.680 |
Why?
| | Retinal Ganglion Cells | 6 | 2022 | 118 | 0.610 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.600 |
Why?
| | Corneal Injuries | 3 | 2024 | 50 | 0.590 |
Why?
| | Tissue Scaffolds | 2 | 2020 | 214 | 0.570 |
Why?
| | Collagen | 2 | 2020 | 457 | 0.570 |
Why?
| | Mustard Gas | 3 | 2024 | 106 | 0.560 |
Why?
| | Chemical Warfare Agents | 3 | 2024 | 117 | 0.560 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1552 | 0.530 |
Why?
| | Biocompatible Materials | 2 | 2020 | 434 | 0.510 |
Why?
| | Epithelial-Mesenchymal Transition | 4 | 2021 | 214 | 0.420 |
Why?
| | Tomography, Optical Coherence | 2 | 2019 | 260 | 0.390 |
Why?
| | Lens, Crystalline | 3 | 2021 | 133 | 0.390 |
Why?
| | Prostaglandins F | 1 | 2011 | 16 | 0.360 |
Why?
| | Retrospective Studies | 14 | 2025 | 16626 | 0.330 |
Why?
| | Risk Assessment | 1 | 2019 | 3562 | 0.300 |
Why?
| | Capsule Opacification | 2 | 2020 | 22 | 0.300 |
Why?
| | Nerve Fibers | 1 | 2009 | 101 | 0.300 |
Why?
| | Humans | 41 | 2025 | 142526 | 0.290 |
Why?
| | Epithelial Cells | 3 | 2021 | 1116 | 0.290 |
Why?
| | Transforming Growth Factor beta2 | 2 | 2021 | 36 | 0.290 |
Why?
| | Postoperative Complications | 2 | 2022 | 2862 | 0.260 |
Why?
| | Postoperative Period | 5 | 2025 | 360 | 0.260 |
Why?
| | Treatment Outcome | 8 | 2025 | 11298 | 0.250 |
Why?
| | Inflammation | 1 | 2018 | 2867 | 0.250 |
Why?
| | Eye | 2 | 2006 | 114 | 0.250 |
Why?
| | Refraction, Ocular | 2 | 2024 | 43 | 0.240 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2007 | 84 | 0.240 |
Why?
| | Stents | 3 | 2021 | 539 | 0.230 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 230 | 0.230 |
Why?
| | Glaucoma Drainage Implants | 2 | 2021 | 45 | 0.230 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.230 |
Why?
| | Aged | 15 | 2025 | 25117 | 0.220 |
Why?
| | Cornea | 4 | 2024 | 159 | 0.220 |
Why?
| | Lens Implantation, Intraocular | 3 | 2022 | 67 | 0.210 |
Why?
| | Gelatin | 1 | 2024 | 57 | 0.210 |
Why?
| | Photorefractive Keratectomy | 1 | 2024 | 20 | 0.210 |
Why?
| | Lasers, Excimer | 1 | 2024 | 29 | 0.210 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2024 | 20 | 0.210 |
Why?
| | Printing, Three-Dimensional | 1 | 2024 | 95 | 0.200 |
Why?
| | Aged, 80 and over | 7 | 2025 | 8020 | 0.200 |
Why?
| | Iritis | 1 | 2023 | 1 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 47 | 0.200 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2022 | 58 | 0.190 |
Why?
| | Follow-Up Studies | 5 | 2025 | 5270 | 0.180 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2021 | 32 | 0.170 |
Why?
| | Kynurenine 3-Monooxygenase | 1 | 2020 | 5 | 0.160 |
Why?
| | Kynurenic Acid | 1 | 2020 | 18 | 0.160 |
Why?
| | Posterior Capsule of the Lens | 1 | 2020 | 11 | 0.160 |
Why?
| | Hepatitis C | 1 | 2022 | 253 | 0.160 |
Why?
| | Ophthalmology | 1 | 2001 | 106 | 0.150 |
Why?
| | Male | 19 | 2025 | 70910 | 0.150 |
Why?
| | Animals | 17 | 2024 | 37697 | 0.150 |
Why?
| | Disease Models, Animal | 5 | 2022 | 4483 | 0.140 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 201 | 0.140 |
Why?
| | Middle Aged | 11 | 2025 | 35049 | 0.140 |
Why?
| | Aldehyde Reductase | 1 | 2018 | 29 | 0.140 |
Why?
| | Rabbits | 3 | 2024 | 664 | 0.140 |
Why?
| | Prosthesis Implantation | 2 | 2018 | 156 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 21 | 0.140 |
Why?
| | Hydrogels | 1 | 2024 | 690 | 0.130 |
Why?
| | Dexamethasone | 3 | 2024 | 377 | 0.130 |
Why?
| | Reperfusion Injury | 1 | 2020 | 292 | 0.130 |
Why?
| | Risk Factors | 3 | 2022 | 10593 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 351 | 0.130 |
Why?
| | Female | 14 | 2025 | 76624 | 0.120 |
Why?
| | Microscopy, Electron, Scanning | 2 | 2007 | 202 | 0.120 |
Why?
| | Aspirin | 1 | 2020 | 396 | 0.120 |
Why?
| | Stem Cells | 1 | 2001 | 612 | 0.120 |
Why?
| | Filtering Surgery | 1 | 2016 | 22 | 0.120 |
Why?
| | Crystallins | 1 | 2016 | 61 | 0.120 |
Why?
| | Glaucoma, Neovascular | 1 | 2015 | 10 | 0.120 |
Why?
| | Perception | 1 | 2018 | 378 | 0.110 |
Why?
| | Drug Packaging | 1 | 2015 | 43 | 0.110 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 108 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 837 | 0.110 |
Why?
| | Histones | 1 | 2020 | 655 | 0.110 |
Why?
| | Actins | 3 | 2024 | 427 | 0.110 |
Why?
| | Caspases | 3 | 2005 | 245 | 0.100 |
Why?
| | Patient Preference | 1 | 2016 | 208 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 672 | 0.090 |
Why?
| | Ophthalmic Solutions | 3 | 2018 | 80 | 0.090 |
Why?
| | Incidence | 1 | 2019 | 2826 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 16 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 513 | 0.080 |
Why?
| | Corneal Edema | 1 | 2010 | 4 | 0.080 |
Why?
| | Mice | 7 | 2022 | 18172 | 0.080 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 1 | 2010 | 6 | 0.080 |
Why?
| | Swine | 2 | 2016 | 832 | 0.080 |
Why?
| | Adult | 7 | 2025 | 39715 | 0.080 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2009 | 50 | 0.080 |
Why?
| | Visual Fields | 1 | 2009 | 117 | 0.070 |
Why?
| | Cell Culture Techniques | 2 | 2024 | 372 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 5994 | 0.070 |
Why?
| | Sclera | 1 | 2007 | 38 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2053 | 0.060 |
Why?
| | Intravitreal Injections | 2 | 2018 | 61 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2020 | 3081 | 0.060 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 36 | 0.060 |
Why?
| | Autopsy | 1 | 2006 | 98 | 0.060 |
Why?
| | Prospective Studies | 4 | 2021 | 7862 | 0.060 |
Why?
| | Optic Nerve | 1 | 2006 | 66 | 0.060 |
Why?
| | United States | 2 | 2023 | 15447 | 0.060 |
Why?
| | Young Adult | 2 | 2019 | 13878 | 0.060 |
Why?
| | Administration, Topical | 2 | 2016 | 151 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Optic Nerve Injuries | 1 | 2005 | 9 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 15 | 0.060 |
Why?
| | Preoperative Period | 2 | 2019 | 144 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 81 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2024 | 4167 | 0.050 |
Why?
| | Refractive Errors | 1 | 2024 | 35 | 0.050 |
Why?
| | Methacrylates | 1 | 2024 | 120 | 0.050 |
Why?
| | Tacrolimus | 1 | 2005 | 200 | 0.050 |
Why?
| | Irritants | 1 | 2024 | 44 | 0.050 |
Why?
| | Myopia | 1 | 2024 | 55 | 0.050 |
Why?
| | Mechlorethamine | 1 | 2024 | 59 | 0.050 |
Why?
| | Perfusion | 1 | 2024 | 240 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 101 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2023 | 5 | 0.050 |
Why?
| | Phenylacetates | 1 | 2023 | 10 | 0.050 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2003 | 26 | 0.050 |
Why?
| | Benzeneacetamides | 1 | 2023 | 8 | 0.050 |
Why?
| | Acetazolamide | 1 | 2023 | 26 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 19 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 281 | 0.050 |
Why?
| | Axonal Transport | 1 | 2022 | 26 | 0.050 |
Why?
| | Adolescent | 2 | 2019 | 22326 | 0.050 |
Why?
| | Laminin | 1 | 2022 | 72 | 0.050 |
Why?
| | Neuroprotection | 1 | 2022 | 44 | 0.050 |
Why?
| | Blindness | 1 | 2022 | 50 | 0.050 |
Why?
| | Rats | 4 | 2022 | 5585 | 0.050 |
Why?
| | Cell Line | 2 | 2020 | 2878 | 0.050 |
Why?
| | Retinal Detachment | 1 | 2003 | 75 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 154 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2022 | 140 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2024 | 453 | 0.040 |
Why?
| | Ligands | 1 | 2024 | 669 | 0.040 |
Why?
| | Algorithms | 1 | 2009 | 1791 | 0.040 |
Why?
| | Intraoperative Complications | 1 | 2022 | 150 | 0.040 |
Why?
| | Manometry | 1 | 2021 | 97 | 0.040 |
Why?
| | Signal Transduction | 3 | 2021 | 5163 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2024 | 510 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 242 | 0.040 |
Why?
| | Molecular Chaperones | 1 | 2022 | 198 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 566 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 859 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2020 | 86 | 0.040 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2020 | 106 | 0.040 |
Why?
| | Rats, Inbred BN | 3 | 2005 | 54 | 0.040 |
Why?
| | Caspase 9 | 3 | 2005 | 57 | 0.040 |
Why?
| | Acetylation | 1 | 2020 | 248 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 16 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 39 | 0.040 |
Why?
| | Circadian Rhythm | 1 | 2023 | 510 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2022 | 556 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 5967 | 0.030 |
Why?
| | Enzyme Activation | 3 | 2005 | 785 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1152 | 0.030 |
Why?
| | Microscopy | 1 | 2018 | 156 | 0.030 |
Why?
| | Cadherins | 1 | 2018 | 201 | 0.030 |
Why?
| | Cell Count | 2 | 2010 | 320 | 0.030 |
Why?
| | Porosity | 1 | 2016 | 101 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 530 | 0.030 |
Why?
| | Snail Family Transcription Factors | 1 | 2016 | 18 | 0.030 |
Why?
| | Smad3 Protein | 1 | 2016 | 44 | 0.030 |
Why?
| | Smad2 Protein | 1 | 2016 | 38 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 985 | 0.030 |
Why?
| | Smad4 Protein | 1 | 2016 | 35 | 0.030 |
Why?
| | Biomimetic Materials | 1 | 2016 | 71 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 545 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 889 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5700 | 0.030 |
Why?
| | Registries | 1 | 2023 | 2227 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 97 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 644 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 969 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 988 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3362 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 2 | 2003 | 126 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2180 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1829 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 547 | 0.020 |
Why?
| | Blotting, Western | 2 | 2005 | 1220 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2514 | 0.020 |
Why?
| | Corneal Diseases | 1 | 2010 | 45 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2005 | 1727 | 0.020 |
Why?
| | Organ Size | 1 | 2010 | 478 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2608 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2010 | 855 | 0.020 |
Why?
| | Molteno Implants | 1 | 2006 | 2 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 767 | 0.020 |
Why?
| | Depression, Chemical | 1 | 2005 | 19 | 0.010 |
Why?
| | Nerve Crush | 1 | 2005 | 8 | 0.010 |
Why?
| | Calcineurin | 1 | 2005 | 108 | 0.010 |
Why?
| | Apoptosis | 2 | 2003 | 2500 | 0.010 |
Why?
| | Prosthesis Design | 1 | 2006 | 346 | 0.010 |
Why?
| | Caspase 7 | 1 | 2003 | 22 | 0.010 |
Why?
| | Enzyme Precursors | 1 | 2002 | 15 | 0.010 |
Why?
| | Time Factors | 2 | 2005 | 7006 | 0.010 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2003 | 99 | 0.010 |
Why?
| | Retina | 1 | 2005 | 318 | 0.010 |
Why?
| | Staining and Labeling | 1 | 2002 | 152 | 0.010 |
Why?
| | Immunoblotting | 1 | 2002 | 309 | 0.010 |
Why?
| | Caspase 3 | 1 | 2003 | 249 | 0.010 |
Why?
|
|
Pantcheva's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|